LSLi-Bing Song

Li-Bing Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Li-Bing Song has a total of 181 co-authors. Here are the top co-authors by number of shared publications:

  • Jun Li

    Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong Province, China

    8 shared publications
  • Mu-Sheng Zeng

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

    8 shared publications
  • Jueheng Wu

    Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

    7 shared publications
  • Jun Li

    China University of Geosciences

    6 shared publications
  • Mengfeng Li

    Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China

    6 shared publications
  • Ling Shi

    State Key Laboratory of Oncology in Southern China, Department of Experimental Research, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China

    4 shared publications

Latest Publications

  • Retraction
    Open Access

    Retraction Note to: High expression level and nuclear localization of Sam68 are associated with progression and poor prognosis in colorectal cancer

    by Wen-Ting Liao, Jun-Ling Liu, Zheng-Gen Wang, Yan-Mei Cui, Ling Shi, Ting-Ting Li, Xiao-Hui Zhao, Xiu-Ting Chen, Yan-Qing Ding, Li-Bing Song

  • Open Access

    miR-93 Promotes Cell Proliferation in Gliomas through Activation of PI3K/Akt Signaling Pathway

    by Lili Jiang, Chanjuan Wang, Fangyong Lei, Longjuan Zhang, Xin Zhang, Aibin Liu, Geyan Wu, Jinrong Zhu, Libing Song

    MiR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway miR-93 Promotes Cell Proliferation in Gliomas through Activation of PI3K/Akt Signaling Pathway


  • Open Access

    AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma

    by Yanmei Cui, Chuyong Lin, Zhiqiang Wu, Aibin Liu, Xin Zhang, Jinrong Zhu, Geyan Wu, Jueheng Wu, Mengfeng Li, Jun Li, et al.

    AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma AGK enhances angiogenesis and inhibits apoptosis via activation of the NF-κB signaling pathway in hepatocellular carcinoma


  • Open Access

    URG4 overexpression is correlated with cervical cancer progression and poor prognosis in patients with early-stage cervical cancer

    by Lan Zhang, He Huang, Longjuan Zhang, Teng Hou, Shu Wu, Qidan Huang, Libing Song, Jihong Liu

    Upregulator of cell proliferation 4 (URG4) has been implicated in the oncogenesis of certain cancers. However, the correlation between URG4 expression and clinicopathological significance in human cancer remains unclear. Therefore, this study investigated its expression and clinicopathological significance in cervical cancer patients. URG4 expression was examined using quantitative PCR (qPCR) and western blotting in normal cervical epithelial cells, cervical cancer cells, and eight matched pairs of cervical cancer tissues and adjacent noncancerous tissues from the same patient. In addition, immunohistochemistry (IHC) was used to examine URG4 expression in paraffin-embedded tissues from 167 cervical cancer patients (FIGO stages Ib1-IIa2). Statistical analyses were performed to evaluate associations between URG4 expression and prognostic and diagnostic factors. URG4 was significantly upregulated in the cervical cancer cell lines and tissues compared with the normal cells and adjacent noncancerous cervical tissues. IHC revealed high URG4 expression in 59 out of the 167 (35.13%) cervical cancer specimens. Its expression was significantly correlated with clinical stage (P < 0.0001), tumour size (P = 0.012), T classification (P = 0.023), lymph node metastasis (P = 0.001) and vaginal involvement (P = 0.002). Patients with high URG4 expression, particularly those who received concurrent chemotherapy and radiotherapy (P < 0.0001), showed a shorter overall survival (OS) and disease-free survival (DFS) compared to those with the low expression of this protein. Multivariate analysis revealed that URG4 expression is an independent prognostic factor for cervical cancer patients. Our results demonstrated that elevated URG4 protein expression is associated with a poor outcome in patients with early-stage cervical cancer. URG4 may be a novel prognostic marker and therapeutic target for the treatment of cervical cancer.


  • Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF‐κB pathway

    by Ting Dai, Dongsheng Zhang, Muyan Cai, Chanjuan Wang, Zhiqiang Wu, Zhe Ying, Jueheng Wu, Mengfeng Li, Dan Xie, Jun Li, et al.

    Hepatocellular carcinoma (HCC) is one of the most lethal malignancies, in which the NF‐κB pathway plays an important role and is constitutively activated. Better understanding of the molecular pathogenesis of HCC and the NF‐κB pathway are needed to improve patient outcomes. Herein, we identified an unappreciated protein involved in NF‐κB‐induced activation, Golgi phosphoprotein 3 (GOLPH3). The mRNA and protein expression levels of GOLPH3 were frequently up‐regulated in HCC and GOLPH3 expression correlated closely with clinical stage and survival in both the testing and validation cohorts. Ectopic over‐expression of GOLPH3 in PLC/PRF/5 (PLC) and Huh7 HCC cells protected against cisplatin‐induced apoptosis, promoted angiogenesis and proliferation and increased the aggressiveness of HCC cells in vitro and in vivo, whereas inhibition of GOLPH3 led to decreased aggressiveness. Through analysis of two published HCC patient profiles, GOLPH3 expression significantly correlated with NF‐κB signalling. Furthermore, we demonstrated that GOLPH3 promoted K63‐linked polyubiquitination of tumour necrosis factor receptor‐associated factor 2 (TRAF2), receptor interacting protein (RIP) and NF‐κB essential modulator (NEMO) and substantially sustained the activation of NF‐κB in HCC cells. Taken together, our findings provided evidence that GOLPH3 is a prognostic and/or potential therapeutic biomarker for HCC patients and plays an important role in activation of the NF‐κB pathway during HCC progression. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.


  • Open Access

    Acylglycerol kinase promotes cell proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor

    by Xi Wang, Chuyong Lin, Xiaohui Zhao, Aibin Liu, Jinrong Zhu, Xinghua Li, Libing Song

    Acylglycerol kinase (AGK) is reported to be overexpressed in multiple cancers. The clinical significance and biological role of AGK in breast cancer, however, remain to be established.


  • Open Access

    Flotillin-2 is associated with breast cancer progression and poor survival outcomes

    by Xi Wang, Qi Yang, Ling Guo, Xing-Hua Li, Xiao-Hui Zhao, Li-Bing Song, Huan-Xin Lin

    Background: Flotillin-2 (FLOT2) has been implicated in several signaling pathways in tumor cells. Our study aimed to investigate the expression pattern and clinicopathological significance of FLOT2 in patients with breast cancer. Methods: The expression level of FLOT2 in normal breast epithelial cells, breast cancer cell lines, and four breast cancer biopsies paired with adjacent noncancerous tissues were quantified using real-time RT-PCR and Western blotting. FLOT2 protein expression was analyzed in 171 archived paraffin-embedded breast cancer samples using immunohistochemistry (IHC). Statistical analyses were performed to evaluate the clinicopathological significance of FLOT2 expression. Results: FLOT2 was significantly upregulated in breast cancer cell lines and tissue samples compared with normal cells and adjacent noncancerous breast tissues, respectively. IHC analysis revealed high expression levels of FLOT2 in 82 of 171 (48.0%) breast cancer specimens. Statistical analysis revealed that FLOT2 expression was significantly correlated with clinical stage (P < 0.001), T classification (P < 0.001), M classification (P < 0.001), histological differentiation (P = 0.005) and ErbB2 expression (P = 0.003). Patients with higher levels of FLOT2 expression had a shorter overall survival duration than patients with lower FLOT2 expression levels. Multivariate analysis suggested that FLOT2 expression was an independent prognostic marker for survival in patients with breast cancer. Conclusions: The current results demonstrated that high FLOT2 protein expression was associated with poor outcomes in patients with breast cancer. FLOT2 could be used as a prognostic biomarker for breast cancer progression.


  • Retracted
    Open Access

    RETRACTED ARTICLE: High expression level and nuclear localization of Sam68 are associated with progression and poor prognosis in colorectal cancer

    by Wen-Ting Liao, Jun-Ling Liu, Zheng-Gen Wang, Yan-Mei Cui, Ling Shi, Ting-Ting Li, Xiao-Hui Zhao, Xiu-Ting Chen, Yan-Qing Ding, Li-Bing Song

    Background: Src-associated in mitosis (Sam68; 68 kDa) has been implicated in the oncogenesis and progression of several human cancers. The aim of this study was to investigate the clinicopathologic significance of Sam68 expression and its subcellular localization in colorectal cancer (CRC). Methods: Sam68 expression was examined in CRC cell lines, nine matched CRC tissues and adjacent noncancerous tissues using reverse transcription (RT)-PCR, quantitative RT-PCR and Western blotting. Sam68 protein expression and localization were determined in 224 paraffin-embedded archived CRC samples using immunohistochemistry. Statistical analyses were applied to evaluate the clinicopathologic significance. Results: Sam68 was upregulated in CRC cell lines and CRC, as compared with normal tissues; high Sam68 expression was detected in 120/224 (53.6%) of the CRC tissues. High Sam68 expression correlated significantly with poor differentiation ( P = 0.033), advanced T stage ( P < 0.001), N stage ( P = 0.023) and distant metastasis ( P = 0.033). Sam68 nuclear localization correlated significantly with poor differentiation ( P = 0.002) and T stage ( P =0.021). Patients with high Sam68 expression or Sam68 nuclear localization had poorer overall survival than patients with low Sam68 expression or Sam68 cytoplasmic localization. Patients with high Sam68 expression had a higher risk of recurrence than those with low Sam68 expression. Conclusions: Overexpression of Sam68 correlated highly with cancer progression and poor differentiation in CRC. High Sam68 expression and Sam68 nuclear localization were associated with poorer overall survival.


  • Downregulation of miR-452 Promotes Stem-Like Traits and Tumorigenicity of Gliomas

    by Liping Liu, Kun Chen, Jueheng Wu, Ling Shi, Bo Hu, Shiyuan Cheng, Mengfeng Li, Libing Song

    Purpose: miR-452 is reported to be required for neural crest stem cell differentiation during neural crest development. However, the biologic role of miR-452 in gliomas remains unclear. The aim of the present study was to evaluate the effect of miR-452 on the stem-like properties and tumorigenesis of glioma cells. Experimental Design: The expression of miR-452 was examined in glioma cells and glioma tissues using real-time PCR. The effects of miR-452 on stem-like traits and tumorigenesis were investigated in vitro and in vivo using patient-derived glioma cells and glioma cell lines. Western blotting and luciferase reporter assays were conducted to examine the negative regulation of Bmi-1, LEF1, and TCF4 by miR-452. The methylation of the miR-452 promoter region was examined by bisulfite genomic sequencing PCR. Results: miR-452 was markedly downregulated in glioma cells and clinical glioma tissues. miR-452 levels were inversely correlated with World Health Organization (WHO) grades and patient survival. miR-452 directly targeted and suppressed multiple stemness regulators, including Bmi-1, LEF1, and TCF4, resulting in reduced stem-like traits and tumorigenesis of glioma cells in vitro and in vivo. Furthermore, we showed that downregulation of miR-452 in gliomas was caused by hypermethylation of its promoter region. Conclusions: Downregulation of miR-452 plays an important role in promoting the stem-like traits and tumorigenesis of gliomas and may represent a novel prognostic biomarker and therapeutic target for the disease. Clin Cancer Res; 19(13); 3429–38. ©2013 AACR.


  • Open Access

    High Expression of FLOT1 Is Associated with Progression and Poor Prognosis in Hepatocellular Carcinoma

    by Shi-Hong Zhang, Chan-Juan Wang, Ling Shi, Xing-Hua Li, Jing Zhou, Li-Bing Song, Wen-Ting Liao

    The flotillin family member flotillin-1 (FLOT1) encodes a caveolae-associated, integral membrane protein that belongs to lipid raft family and involves in vesicular trafficking and signal transduction. However, the role of FLOT1 in development and progression of cancer remains largely unknown. The present study was aimed to investigate the clinical and prognostic significance of FLOT1 in hepatocellular carcinoma (HCC). Real-time PCR and western blot analyses were applied to examine FLOT1 expression in fourteen HCC cell lines and one normal hepatic cell line, ten pairs of primary HCC and matched adjacent noncancerous liver tissues from the same patient. Immunohistochemistry (IHC) was performed to examine FLOT1 protein expression in paraffin-embedded tissues from 196 HCC patients. Statistical analyses were applied to evaluate the diagnostic value and associations of FLOT1 expression with clinical parameters. FLOT1 expression was evidently up-regulated in HCC tissues compared with that in the matched adjacent noncancerous liver tissues. In the 196 cases of tested HCC samples, FLOT1 protein level was positively correlated with Tumor size (P = 0.025), clinical stage (PPPPP = 0.025). Patients with higher FLOT1 expression had shorter overall survival time, whereas those with lower FLOT1 expression had longer survival time. Our study demonstrated FLOT1 is associated with aggressive characteristics of HCC, and suggested the possibility of its use as a prognostic marker in patients with HCC.